...
首页> 外文期刊>Pharmaceutical research >Polar molecular surface as a dominating determinant for oral absorption and brain penetration of drugs.
【24h】

Polar molecular surface as a dominating determinant for oral absorption and brain penetration of drugs.

机译:极性分子表面是决定药物口服吸收和脑渗透的主要决定因素。

获取原文
获取原文并翻译 | 示例
           

摘要

PURPOSE: To study oral absorption and brain penetration as a function of polar molecular surface area. METHODS: Measured brain penetration data of 45 drug molecules were investigated. The dynamic polar surface areas were calculated and correlated with the brain penetration data. Also the static polar surface areas of 776 orally administered CNS drugs that have reached at least Phase II efficacy studies were calculated. The same was done for a series of 1590 orally administered non-CNS drugs that have reached at least Phase II efficacy studies. RESULTS: A linear relationship between brain penetration and dynamic polar surface area (A2) was found (n = 45, R = 0.917, F1,43 = 229). Brain penetration decreases with increasing polar surface area. A clear difference between the distribution of the polar surface area of the 776 CNS and 1590 non-CNS drugs was found. It was deduced that orally active drugs that are transported passively by the transcellular route should not exceed a polar surface area of about 120 A2. They can be tailored to brain penetration by decreasing the polar surface to <60-70 A2. This conclusion is supported by the inverse linear relationship between experimental brain penetration data and the dynamic polar surface area of 45 drug molecules. CONCLUSIONS: The polar molecular surface area is a dominating determinant for oral absorption and brain penetration of drugs that are transported by the transcellular route. This property should be considered in the early phase of drug screening.
机译:目的:研究口服吸收和脑渗透与极性分子表面积的关系。方法:调查了45种药物分子的脑渗透数据。计算了动态极表面积,并将其与脑渗透数据相关联。还计算了至少达到II期功效研究的776种口服CNS药物的静态极性表面积。对一系列至少达到II期疗效研究的1590种口服非CNS药物进行了同样的处理。结果:发现大脑渗透与动态极性表面积(A2)之间呈线性关系(n = 45,R = 0.917,F1,43 = 229)。脑渗透率随着极性表面积的增加而降低。发现776种CNS和1590种非CNS药物的极性表面积分布之间存在明显差异。据推论,通过跨细胞途径被动运输的口服活性药物不应超过约120 A2的极性表面积。可以通过将极性表面减小到<60-70 A2来定制脑部穿透能力。实验脑部渗透数据与45种药物分子的动态极性表面积之间的反线性关系支持了这一结论。结论:极性分子表面积是决定药物通过口服途径吸收和脑部渗透的主要决定因素。在药物筛选的早期阶段应考虑此属性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号